Uterine Fibroid Treatment Market By Type 2022 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Uterine Fibroid Treatment Market
Uterine Fibroid Treatment Market: By Type (Subserosal Fibroids, Intramural Fibroids, Others); By Treatment (Non-Hormonal, Hormonal, Surgical) & By Region-Forecast (2016-2022)
Report Code : HCR 0710
Updated Date: 07 September, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Uterine fibroid is a type of tumour that grows in the muscular wall of the uterus. It occurs mainly in about 20%–40% in women during their reproductive ages. Globally, development of efficient and advanced technology, rise in the awareness among people regarding diseases, increasing government initiatives across the globe, growing prevalence of uterine fibroids and change in lifestyle mainly dietary pattern, and rising number of women of reproductive age (WRA) across the globe are the prime growth drivers of the uterine fibroid treatment market. In addition, an increase in adoption of uterine fibroid treatment in emerging economies such as China, India and others, will create new opportunities for the uterine fibroid treatment market. However, higher cost of research and development are the key restraints for the uterine fibroid treatment market.

 Uterine Fibroid Treatment Market

Geographically, North America dominated the uterine fibroid treatment market, because of higher number of patients suffering from uterine fibroid problem (20 million women in North America), high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have the fastest growth, owing to a rapidly increasing women population, rise in awareness, favourable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region. Among all the types, intramural fibroids has the highest market share in the uterine fibroid treatment market.

This report identifies the uterine fibroid treatment market size for the years 2014-2016, and forecast of the same till the year 2022. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the uterine fibroid treatment market.

This report segments the uterine fibroid treatment market on the basis of type, treatment, and regional market as follows:
  • Uterine Fibroid Treatment Market, By Type: Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, and Pedunculated Fibroids
  • The report has focused study on uterine fibroid treatment market by basis of treatment such as: Non-Hormonal Treatment, Hormonal Treatment, and Surgical Methods
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the uterine fibroid treatment market. Some of the major companies’ profiles in detail are as follows:
  • F. Hoffmann-La Roche Ltd
  • Boston Scientific Corporation
  • Richard Wolf Medical Instruments
  • Eli Lilly and Company
  • GlaxoSmithKline Pharmaceuticals Limited
1. Uterine Fibroid Treatment Market – Overview
2. Executive Summary 
3. Uterine Fibroid Treatment Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Uterine Fibroid Treatment Market– Forces
   4.1. Drivers
      4.1.1. Development of efficient and advance technology
      4.1.2. Growing prevalence of uterine fibroids and change in lifestyle mainly dietary pattern
   4.2. Restraints
      4.2.1. Higher cost of research and development 
   4.3. Opportunities
      4.3.1. Emerging economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Uterine Fibroid Treatment Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Uterine Fibroid Treatment Market, By Type
   6.1. Subserosal Fibroids
   6.2. Intramural Fibroids
   6.3. Submucosal Fibroids 
   6.4. Pedunculated Fibroids
7. Uterine Fibroid Treatment Market, By Treatment 
   7.1. Non-Hormonal Treatment
   7.2. Hormonal Treatment
   7.3. Surgical Methods
8. Uterine Fibroid Treatment Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America 
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Uterine Fibroid Treatment – Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   10.1. F. Hoffmann-La Roche Ltd
   10.2. Boston Scientific Corporation
   10.3. Richard Wolf Medical Instruments
   10.4. Eli Lilly and Company
   10.5. GlaxoSmithKline Pharmaceuticals Limited
   10.6. Bayer AG
   10.7. Pfizer Inc.
   10.8. Johnson & Johnson
   10.9. Novartis AG
   10.10. Siemens Medical Solutions
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix
   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll